Site search

Clear filter
2863 results for '' found
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN
/
An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Ob
An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Ob
/
Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)
Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)
/
Brain Oxygen Neuromonitoring in Australia and New Zealand Assessment - Global Trial (BONANZA-GT) (ACTRN12619001328167)
Brain Oxygen Neuromonitoring in Australia and New Zealand Assessment - Global Trial (BONANZA-GT) (ACTRN12619001328167)
/
A Study to Evaluate Cavrotolimod in Subjects with Chronic Hepatitis B Virus [HBV] Infection (ACTRN12624000809538)
A Study to Evaluate Cavrotolimod in Subjects with Chronic Hepatitis B Virus [HBV] Infection (ACTRN12624000809538)
/
BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)
BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)
/
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With
/
BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509
/
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Pati
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Pati
/
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabin
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabin
/
59 60 61 62 63